Crizotinib
- PDF / 122,009 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 6 Downloads / 190 Views
1
Crizotinib Sinus bradycardia: 3 case reports Two women and one man with non-small cell lung cancer developed sinus bradycardia during treatment with oral crizotinib 250mg twice daily. A 32-year-old woman started receiving cizotinib in March 2010. Within 2 weeks of therapy initiation, asymptomatic profound sinus bradycardia with a HR of ≤ 45 emerged; before cizotinib start, her baseline HR was 84. Sinus bradycardia persisted throughout treatment, but other ECG findings and her BP remained normal. Treatment was continued without interruption or dose adjustment until disease progression in November 2010. An 80-year-old woman started receiving crizotinib in May 2010. On day 1, her HR and PR interavl were 67 and 230ms, respectively. Within 4 weeks, she achieved a partial response, but serial ECGs simultaneously revealed sinus bradycardia of 48–51; her PR intervals were 211–217ms. On follow-up in June 2011, profound sinus bradycardia with a HR of ≤ 45 was evident, but she remained asymptomatic. At last follow-up on 20 July 2011, crizotinib had been continued at the same dosage and without interruption. A 50-year-old man started receiving crizotinib in midAugust 2010. On treatment day 1, serial ECGs revealed HRs of 54–62, but sinus bradycardia with HR between 51 and 54 had devleoped 2 weeks later. Profound sinus bradycardia with a HR of ≤ 45 was evident by March 2011, but he continued to exercise and remained asymptomatic. In July 2011, his HR was 39. Treatment had been continued without dosage adjustment or interruption at last follow-up on 20 July 2011, and his performance status had remained unchanged. Ou S-HI, et al. Asymptomatic profound sinus bradycardia (heart rate ≤45) in nonsmall cell lung cancer patients treated with crizotinib. Journal of Thoracic Oncology 6: 2135-2137, No. 12, Dec 2011. Available from: URL: http:// 803066560 dx.doi.org/10.1097/jto.0b013e3182307e06 - USA
0114-9954/10/1387-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 4 Feb 2012 No. 1387
Data Loading...
